[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
April 1989

Double-blind Randomized Placebo-Controlled Trial of Local Cyclosporine in Atopic Dermatitis

Author Affiliations

Service de Dermatologie Hôpital Necker Enfants Malades 149 rue de Sèvres F75743 Paris, France

Arch Dermatol. 1989;125(4):570. doi:10.1001/archderm.1989.01670160118034

To the Editor.—  Oral cyclosporine A administered at a low dose of 5 mg/kg per day improves severe atopic dermatitis.1 The therapeutic action of locally administered cyclosporine has been reported in experimental animals in a model of dinitrofluorobenzene contact eczema, and in man in the course of alopecia areata.2-7 Therefore, we investigated the efficacy of topical cyclosporine A in stable lesions of atopic dermatitis. Twenty patients (aged between 2 and 29 years [mean, 11.6 ± 7.5 years]) suffering from atopic dermatitis and presenting with stable, symmetrical lesions participated in this study after giving their informed consent. The patients were supplied with tubes containing an oily alcohol gel that contained either 100 mg/g of cyclosporine A (Sandimmun, Sandoz) or excipient alone. The cyclosporine A gel and placebo gel were randomly allocated to the left and right sides. Patients did not use other local therapy on the lesions, except for

First Page Preview View Large
First page PDF preview
First page PDF preview